Transforming First-Line Treatment for ALK+ NSCLC
In an interview with CURE, Leena Gandhi, M.D., Ph.D., discussed emerging developments in the first-line treatment for patients with ALK-positive NSCLC, as well as novel agents emerging in the field.
Read More
Big Change May Be Coming for Frontline NSCLC
The results of phase 3 FLAURA trial could potentially change the treatment paradigm for some patients with lung cancer.
Combinations Are Showing Promise in MCL
Andre Goy, M.D., discusses some exciting advances in mantle cell lymphoma (MCL).
Immunotherapy in GI Cancers: Who Gets It?
What role will immunotherapy play in the future treatment of GI cancers? CURE spoke to Brian Hemphill, M.D., to find out.
Paradigm-Shifting Change May Be Coming in Melanoma
An ongoing trial studying Keytruda (pembrolizumab) with the first-in-class IDO1 inhibitor epacadostat (INCB024360) can mean drastic change for patients with melanoma.
Surgery Is Still Crucial for Melanoma Treatment
Kiran K. Turaga explains that, even with all the advancements and novel treatments in melanoma, surgery is still critical.
Advancing Immunotherapy Impact in Bladder Cancer
In an interview with CURE, Arlene O. Siefker-Radtke, M.D., discusses immune treatment and the immune landscape for the treatment of patients with urothelial cancers.
New Advances in Gastroesophageal Cancers
Dr. Daniel H. Ahn, D.O., spoke with CURE about new advances in gastroesophageal cancers including immunotherapies and stemness inhibitors.
Individualized mCRC Treatment Approaches Increase Efficacy and Aid in Quality of Life
Researchers aim to improve patient outcomes by working on individualized metastatic colorectal cancer treatments.
Weill Cornell Expert, "General Hospital" Actress Unite to Raise PV Awareness
Finola Hughes from TV's "General Hospital" and Ellen K. Ritchie, M.D. are teaming up to raise awareness for polycythemia vera.
Another Year of Lung Cancer Advancements Expected in 2017
2016 was an exciting year for non-small cell lung cancer, and more advances are expected for 2017.
Big Change Is Coming for the Treatment of Triple-Negative Breast Cancer
The treatment landscape of triple-negative breast cancer is vastly changing. CURE spoke with Joyce A. O’Shaughnessy, M.D. about what to expect.
Treatment Is Expanding for HER2-Positive Breast Cancer
There have been exciting developments in the field of HER2-positive breast cancer.
Doing Away With Breast Cancer Surgery
A study being conducted at the MD Anderson Cancer Center is looking at whether certain patients with breast cancer can forgo surgery.
Expert Discusses Molecular Testing and the Future of Breast Cancer Care
Jenny C. Chang, M.D., discusses the future of breast cancer care, and what role molecular testing will play.
Changing the Frontline Treatment of Kidney Cancer
After the approvals of agents in the second-line setting, researchers are now turning to improving the frontline treatment of kidney cancer.
Expert Looks Ahead in the Treatment of MPNs
Michael J. Mauro, M.D., discusses advances in treating myeloproliferative disorders.
Expert Discusses Targetable Mutations and New Agents in Lung Cancer
New advancements are quickly advancing the treatment landscape of lung cancer.
Looking Ahead: Xofigo's Role in Metastatic Prostate Cancer
Xofigo's role in the treatment of metastatic castration-resistant prostate cancer will continue to change.
What's In Store for Hematologic Malignancies?
Andrew D. Zelenetz, M.D., Ph.D. weighs in on recent research and the future of treating hematologic malignancies.
Transplant Is a Mainstay in Hematologic Cancers, Expert Says
Stem cell transplant is still the only curative treatment option for many hematologic malignancies, even as novel drugs continue to emerge.
Liquid Biopsies Are Important in Lung Cancer, Expert Says
Liquid biopsies are quick, convenient and a crucial part of planning treatment for many patients with lung cancer, says Luis E. Raez, M.D.
Change Is on the Way for HR+ Breast Cancer Care
Novel combinations may lead to the future of HR+ breast cancer care.
Challenges in Treating Lung Adenocarcinoma
Mohammad Jahanzeb, M.D. discussed the challenges in treating non-driver lung adenocarcinoma.
Expert Discusses Testing for Rare Genetic Mutations in Lung Cancer
Martin Dietrich, M.D., Ph.D., discusses testing for rarer genetic mutations in patients with lung cancer.
New Agents Are Shifting Kidney Cancer Treatment Strategies
Will the newly approved kidney cancer treatments eventually end up in the frontline setting? Expert Chung-Han (Joe) Lee, M.D., weighs in.
Which Lung Cancer Groups Should Get Radiation?
For patients with lung cancer that is limited in its spread, radiation may help. But exactly who should try it, and when?
In the Age of Immunotherapy, Chemotherapy Is Still a Mainstay for Bladder Cancer
As immunotherapy's potential continues to grow in the treatment of bladder cancer, Gopa Iyer, M.D., says that more research needs to be done before it becomes the next new standard.
NCCN Establishes Treatment Guidelines for MPNs
For the first time in history, MPN guidelines have been set by the NCCN.
Lung Cancer Advancements Are Just Beginning, Expert Says
More advancements in lung cancer are bound to be made, says Edgardo S. Santos, M.D.